Cabozantinib in Progressive Medullary Thyroid Cancer

Elisei, Rossella; J. Schlumberger, Martin; P. Müller, Stefan; Schöffski, Patrick; S. Brose, Marcia; H. Shah, Manisha; Licitra, Lisa; Jarzab, Barbara; Medvedev, Viktor; C. Kreissl, Michael; Niederle, Bruno; E.W. Cohen, Ezra; J. Wirth, Lori; Ali, Haythem; Hessel, Colin; Yaron, Yifah; Ball, Douglas; Nelkin, Barry; I. Sherman, Steven

doi:10.1200/jco.2012.48.4659

Public

Cabozantinib in Progressive Medullary Thyroid Cancer

Shared by NobleBlocks on Oct 10, 2013 • 12:00 AM UTC

Authors:

Rossella Elisei

Martin J. Schlumberger

Stefan P. Müller

Abstract

Purpose Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I. Patients and Methods...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!